Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trastuzumab Deruxtecan,Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
ENHERTU Plus Pertuzumab Shows Strong PFS Benefit in HER2+ Breast Cancer
Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed ADC which is being evaluated in combination with pertuzumab for the treatment of 1st-line therapy for patients with HER2+ metastatic breast cancer.
Product Name : Enhertu
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : Trastuzumab Deruxtecan,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab,Trastuzumab,Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Validates Henlius and Organon Filing for Perjeta Biosimilar HLX11
Details : HLX11 (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with rastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Product Name : HLX11
Product Type : Antibody
Upfront Cash : Inapplicable
March 28, 2025
Lead Product(s) : Pertuzumab,Trastuzumab,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab,Docetaxel,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of Perjeta® Biosimilar HLX11 Meets Primary Endpoint
Details : HLX11 (pertuzumab biosimilar) is the HER2 humanized monoclonal antibody, which is being investigated for the treatment of HER2-positive/ HR-negative locally advanced breast cancer.
Product Name : HLX11
Product Type : Antibody
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Pertuzumab,Docetaxel,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus and Dr. Reddy’s License Agreement for Co-Marketing Pertuzumab Biosimilar in India
Details : Under the agreement, product will be marketed by Zydus under the brand Sigrima while Dr. Reddy’s will market it under brand name Womab used for treatment of Breast Cancer.
Product Name : Womab
Product Type : Antibody
Upfront Cash : Undisclosed
June 28, 2024
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Pertuzumab,Trastuzumab,Vorhyaluronidase Alpha
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phesgo (pertuzumab and trastuzumab) is the HER2 humanized monoclonal antibody, which is indicated for the treatment of HER2-positive breast cancer and Advanced or recurrent HER2-positive colorectal cancer.
Product Name : Phesgo
Product Type : Antibody
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : Pertuzumab,Trastuzumab,Vorhyaluronidase Alpha
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phesgo (pertuzumab and trastuzumab) is the HER2 humanized monoclonal antibody, which is indicated for the treatment of HER2-positive breast cancer and Advanced or recurrent HER2-positive colorectal cancer.
Product Name : Phesgo
Product Type : Antibody
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Pertuzumab,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-Positive Breast Cancer.
Product Name : BDC-1001
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Roche will provide pertuzumab in support of a Phase 2 metastatic breast cancer trial to evaluate pertuzumab in combination with BDC-1001.
Product Name : BDC-1001
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
March 29, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EG1206A (pertuzumab) targets the extracellular dimerization domain (Subdomain II) of the HER2 and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4.
Product Name : EG1206A
Product Type : Antibody
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pertuzumab,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NDA for fixed-dose subcutaneous combination of RG6264 (pertuzumab) and trastuzumab (same monoclonal antibodies as in perjeta and herceptin), based on data including results from global phase III FeDeriCa study in patients with HER2-positive breast cancer...
Product Name : Phesgo
Product Type : Antibody
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : Pertuzumab,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable